Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology

Published:2016-02-27 Issue:5 Volume:36 Page:613-625
ISSN:0172-8172
Container-title:Rheumatology International
language:en
Short-container-title:Rheumatol Int

Author:

Mysler Eduardo,Pineda Carlos,Horiuchi Takahiko,Singh Ena,Mahgoub Ehab,Coindreau Javier,Jacobs Ira

Funder

Pfizer

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy,Rheumatology

Link

http://link.springer.com/content/pdf/10.1007/s00296-016-3444-0.pdf

Reference92 articles.

1. Sahoo N, Choudhury K, Manchikanti P (2009) Manufacturing of biodrugs: need for harmonization in regulatory standards. BioDrugs 23:217–229. doi: 10.2165/11317110-000000000-00000

2. Lee JF, Litten JB, Grampp G (2012) Comparability and biosimilarity: considerations for the healthcare provider. Curr Med Res Opin 28:1053–1058. doi: 10.1185/03007995.2012.686902

3. Braun J, van den Berg R, Baraliakos X et al (2011) 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 70:896–904. doi: 10.1136/ard.2011.151027

4. Smolen JS, Aletaha D, Bijlsma JW et al (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69:631–637. doi: 10.1136/ard.2009.123919

5. Smolen JS, Landewe R, Breedveld FC et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73:492–509. doi: 10.1136/annrheumdis-2013-204573

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physicians’ and patients’ perception of biosimilars and factors affecting biosimilar prescribing in selected Asian Countries: a survey study;Expert Opinion on Biological Therapy;2024-09-05

2. Biosimilar Medicines: From Development Process to Marketing Authorization by the EMA and the FDA;Applied Sciences;2024-08-26

3. In-depth assessment of Iraqi physicians' adherence to treatment guidelines for different diseases: a qualitative study;F1000Research;2024-08-22

4. INVESTIGATING THE PHYSICOCHEMICAL, NON-CLINICAL, AND CLINICAL CRITERIA FOR ASSESSING COMPARABILITY IN RANIBIZUMAB BIOSIMILARS: A COMPREHENSIVE REVIEW;FARMACIA;2024

5. Patient’s and Consultant’s Views and Perceptions on Switching from an Originator Biologic to Biosimilar Medication: A Qualitative Study;Pharmacy;2024-04-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3